Ozempic Gastroparesis Settlement: Statute of Limitations for Ozempic in Washington

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Information to Product Liability

The legacy of general health and science information has long provided a foundation for public understanding of medication risks and legal recourse. Within this broad context, the transition from broad health awareness to specific product liability concerns requires careful navigation. As public discourse evolved, the focus sharpened from general pharmaceutical education to the real-world consequences of drug exposure, particularly when adverse effects emerge after widespread use. This shift is exemplified by the growing attention to glucagon-like peptide-1 receptor agonists, such as Ozempic, which were initially celebrated for metabolic benefits but later scrutinized for potential gastrointestinal complications. The occupational exposure concern here is not limited to healthcare workers handling the drug, but extends to patients who have been prescribed the medication and subsequently developed conditions like gastroparesis—a delayed gastric emptying disorder. In Washington State, the statute of limitations for filing a claim related to such exposure becomes a critical legal parameter, determining the window within which affected individuals may seek compensation. This pivot from general health information to a targeted legal and medical inquiry underscores the need for precise timelines and jurisdictional nuances, moving the discussion from abstract science to actionable patient advocacy.

Understanding Gastroparesis and Its Link to Ozempic

Gastroparesis is a chronic disorder characterized by delayed gastric emptying in the absence of a mechanical obstruction. Clinical presentation typically includes early satiety, postprandial fullness, nausea, vomiting, and abdominal pain. Diagnosis is confirmed through gastric emptying scintigraphy, which measures the rate at which a radiolabeled meal exits the stomach. The condition can significantly impair quality of life and lead to nutritional deficiencies, weight loss, and metabolic disturbances. Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the management of type 2 diabetes. Its pharmacology involves enhancing insulin secretion, suppressing glucagon release, and slowing gastric emptying. The latter effect is central to both its therapeutic action and its potential to cause gastroparesis. In clinical trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo. Specifically, in the pool of placebo-controlled trials, gastrointestinal adverse reactions occurred in 15.3% of placebo patients, 32.7% of those on Ozempic 0.5 mg, and 36.4% of those on Ozempic 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial comparing Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) versus Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions with a frequency of less than 5% included dyspepsia (placebo 1.9%, Ozempic 0.5 mg 3.5%, Ozempic 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Mechanistic Pathway and Warning Adequacy

The mechanistic pathway linking Ozempic to gastroparesis involves the drug's effect on gastric motility. GLP-1 receptor agonists like semaglutide slow gastric emptying by inhibiting vagal nerve activity and reducing antral contractions. This pharmacodynamic effect is intended to improve glycemic control but can become pathological when gastric emptying is excessively delayed, leading to the clinical syndrome of gastroparesis. The risk is dose-dependent, as evidenced by the higher incidence of gastrointestinal adverse reactions at higher doses. The timeline between exposure and documented harm can vary. Some patients experience symptoms during dose escalation, while others may develop gastroparesis after prolonged use. The onset may be insidious, with symptoms such as nausea and vomiting initially attributed to the drug's known gastrointestinal effects, delaying recognition of gastroparesis. Regarding the adequacy of warnings, the prescribing information for Ozempic includes warnings about gastrointestinal adverse reactions but does not explicitly list gastroparesis as a specific adverse reaction. The label notes that serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported, and that caution is warranted in patients with a history of such reactions to other GLP-1 receptor agonists (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the label does not provide a specific warning about the risk of gastroparesis, which may affect the ability of patients and healthcare providers to recognize and manage this condition promptly. This gap in warning information could be relevant in settlement considerations for affected patients, as it may influence claims regarding failure to adequately warn about the risk of gastroparesis.

Statute of Limitations for Ozempic Claims in Washington

Settlement-related considerations for affected patients in Washington must account for the statute of limitations, which governs the time frame within which a legal claim must be filed. In Washington, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally three years from the date the injury was discovered or should have been discovered with reasonable diligence. For claims involving gastroparesis allegedly caused by Ozempic, the clock typically starts when the patient is diagnosed with gastroparesis or when symptoms become severe enough to prompt medical evaluation leading to the diagnosis. The timeline between exposure and documented harm is critical. If a patient began taking Ozempic and developed symptoms of gastroparesis months or years later, the statute of limitations may begin at the time of diagnosis, not at the time of first exposure. Patients should be aware that delays in seeking medical attention or in connecting symptoms to Ozempic use could affect their ability to file a claim within the statutory period. In summary, the evidence indicates that Ozempic is associated with a dose-dependent increase in gastrointestinal adverse reactions, including those that can mimic or cause gastroparesis. The prescribing information does not explicitly warn about gastroparesis, which may be a factor in settlement negotiations. Patients in Washington who have developed gastroparesis after using Ozempic should be mindful of the three-year statute of limitations, which begins upon discovery of the injury. Legal consultation is recommended to assess individual circumstances and ensure timely filing of any potential claims.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic gastroparesis claims in Washington?

In Washington, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally three years from the date the injury was discovered or should have been discovered with reasonable diligence. For gastroparesis allegedly caused by Ozempic, the clock typically starts at diagnosis or when symptoms prompt medical evaluation leading to diagnosis.

Does Ozempic's prescribing information warn about gastroparesis?

The prescribing information for Ozempic includes warnings about gastrointestinal adverse reactions but does not explicitly list gastroparesis as a specific adverse reaction. The label notes serious hypersensitivity reactions but lacks a specific warning about gastroparesis, which may be relevant in settlement considerations regarding failure to adequately warn.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Ozempic Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.